Alteogen

Alteogen Forward P/E

The Forward P/E Ratio of Alteogen (196170.KQ) as of Nov 4, 2026 is 144.21. In the previous year, Forward P/E Ratio was 328.18 — a change of -56.06% (lower).

Forward P/E

144.21

YoY

-56.06%

Last updated:

Forward P/E Ratio of Alteogen is 2025 144.21 . Forward P/E Ratio of Alteogen was 2024 328.18 . It decreases by -56.06% lower compared to the previous year.

The Alteogen Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-2,972.85 KRW
Jan 1, 2019
-28,998.96 KRW
Jan 1, 2020
-21,070.76 KRW
Jan 1, 2021
3,404.44 KRW
Jan 1, 2022
-2,508.00 KRW
Jan 1, 2023
-6,059.19 KRW
Jan 1, 2024
328.18 KRW
Jan 1, 2025
144.21 KRW
The Alteogen Forward P/E history
YEARForward P/EYoY
144.21-56.06%
328.18-105.42%
-6,059.19+141.59%
-2,508.00-173.67%
3,404.44-116.16%
-21,070.76-27.34%
-28,998.96+875.46%
-2,972.85+8.39%
-2,742.69-51.84%
-5,695.29-133.69%
16,907.30-22.94%
21,940.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alteogen Stock analysis

What does Alteogen do? Alteogen, Inc. generates revenue through its biobetter business segment, developing protein pharmaceuticals and cancer therapies, and its bio similar business segment, focusing on bio similar and animal medicines. The company sells growth hormone, herceptin, humira, antibodies, and other products primarily to healthcare providers and pharmaceutical distributors. Its biobetter segment targets oncology and protein-based treatments, while the bio similar segment serves both human and animal health markets with cost-effective alternatives to branded drugs. The firm's product portfolio includes growth hormone, herceptin, and humira, which are key revenue drivers in the biopharmaceutical sector. Herceptin and humira are well-established anticancer drugs, while growth hormone addresses endocrine disorders. The company's bio similar segment offers affordable versions of these therapies, appealing to budget-conscious healthcare systems and veterinary markets. Sales are concentrated in the human and animal medicine sectors, leveraging its dual focus on biobetter and bio similar products. Alteogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alteogen stock

Forward P/E Ratio of Alteogen is 144.21 in 2025.

Forward P/E Ratio of Alteogen changed from 328.18 to 144.21, representing a -56.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Alteogen since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Alteogen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Alteogen

All Key Metrics — Alteogen